AstraZeneca advances the science of cancer medicine with practice-changing data at the ASCO20 Virtual Scientific Program
Data to showcase unprecedented efficacy for Tagrisso in early-stage lung cancer and survival results for Imfinzi in small cell lung cancer
Further data will highlight the transformative potential of Enhertu across multiple HER2-driven tumours and new data for Imfinzi plus tremelimumab in liver cancer and for Lynparza in ovarian cancer
AstraZeneca will present ground-breaking new results across its broad portfolio of cancer medicines during the 2020 American Society of Clinical Oncology ASCO20 Virtual Scientific Program, 29 to 31 May 2020. AstraZeneca will present 98 abstracts, including 19 oral presentations with one plenary and 10 late-breakers.
Presentations will showcase the Company's leadership in the treatment of early lung cancer with a late-breaking plenary presentation of the unprecedented results from the Phase III ADAURA trial for Tagrisso (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Data from the DESTINY programme will highlight the transformative potential of Enhertu (trastuzumab deruxtecan) across HER2-driven tumours, including in lung, breast, gastric and colorectal cancers.
José Baselga, Executive Vice President, Oncology R&D, said: "AstraZeneca continues to deliver results with the goal of transforming clinical practice. Our science at ASCO this year shows the potential for treatment of early-stage EGFR-mutated lung cancer, where we aim to provide the hope of cure with Tagrisso; to rewrite the rules on the treatment of patients with HER2-positive tumours with Enhertu across a range of cancer settings; and to advance our next wave of pipeline medicines focused on treating patients earlier and overcoming resistance."
Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: "One constant throughout these uncertain times is our unwavering commitment to changing the practice of medicine for patients living with cancer. Our new oncology medicines Tagrisso, Imfinzi, Lynparza, and Enhertu are demonstrating incredible momentum at ASCO, building on their established benefits for patients by delivering powerful data in new settings and bending cancer survival curves. This year's data at ASCO reinforce our belief that we can one day eliminate cancer as a cause of death."
Leadership in lung cancer across stages of disease
As AstraZeneca continues to advance lung cancer research and development from early to late-stage settings, the Company will present new data for Tagrisso, Imfinzi (durvalumab), Enhertu, and potential new medicine savolitinib. Beyond ADAURA, an oral presentation of the final analysis of the Phase III CASPIAN trial confirms the sustained, clinically meaningful overall survival (OS) benefit of Imfinzi for patients with extensive-stage small cell lung cancer
(ES-SCLC). Another oral presentation reinforces the potential of Enhertu for patients with HER2-mutant NSCLC (see below). Results from a Phase II trial of savolitinib in patients with mesenchymal-epithelial transition (MET) exon 14 skipping mutations will also be presented.
Transforming treatment across HER2-driven cancers
AstraZeneca, in collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) will present new data from several trials highlighting the transformative potential of Enhertu, including detailed results from the Phase II DESTINY-Gastric01 trial which showed a statistically significant and clinically meaningful improvement in objective response rate and OS for patients with HER2-positive metastatic gastric cancer. Enhertu was recently granted Breakthrough Therapy Designation (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-positive-metastatic-gastric-cancer.html) in the US for patients in this setting. Phase II data will also be presented for HER2-positive colorectal cancer and HER2-mutant NSCLC, two cancer settings for which there are currently no approved HER2-targeted medicines. Additionally, subgroup analyses from the Phase II DESTINY-Breast01 trial will reinforce the durable and consistent responses seen with Enhertu in HER2-positive metastatic breast cancer.
Advancing treatment in other cancer types with high unmet need
AstraZeneca will present data from several trials highlighting how the Company's leading research is progressing treatment in other cancers where a high unmet medical need remains, including:- An oral presentation of results from Study 22 for the Imfinzi plus tremelimumab combination using a novel regimen in advanced liver cancer
- Final OS results from the Phase III SOLO2 trial for Lynparza (olaparib) maintenance treatment in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in an oral presentation. Lynparza is developed and commercialised in collaboration with MSD (MSD: known as Merck & Co., Inc. inside the US and Canada)
- Multiple trials underscoring the impressive profile of Calquence (acalabrutinib), including data from the Phase II ACE-CL-001 trial with more than four years of follow up. The presentations represent the most mature safety and efficacy data to date with Calquence monotherapy in patients with chronic lymphocytic leukaemia
Key AstraZeneca presentations during the ASCO20 Virtual Scientific Program
[]
Lead author Abstract title Presentation details[1]
Immuno
-Oncology
Paz-Ares, L Durvalumab ± Abstract #9002Oral Abstract Session - Lung
tremelimumab + Cancer - Non-Small Cell Local-Regional/Small
platinum Cell/Other Thoracic Cancers
-etoposide in
first-line ES
-SCLC: Results
from the Phase
III CASPIAN study
Chen, Y First-line Abstract #9068Poster #261Poster Session - Lung
durvalumab plus Cancer - Non-Small Cell Local-Regional/Small
platinum Cell/Other Thoracic Cancers
-etoposide in ES
-SCLC (CASPIAN):
Impact of brain
metastases on
treatment
patterns and
outcomes
Naidoo, J Non-pneumonitis Abstract #9048Poster #241Poster Session - Lung
immune-mediated Cancer - Non-Small Cell Local-Regional/Small
adverse events Cell/Other Thoracic Cancers
with durvalumab
in patients with
unresectable,
Stage III NSCLC
(PACIFIC)
Kelley, RK Efficacy, Abstract #4508Oral Abstract Session -
tolerability, and Gastrointestinal Cancer - Gastroesophageal,
biologic activity Pancreatic, and Hepatobiliary
of a novel
regimen of
tremelimumab in
combination with
durvalumab for
patients with
advanced
hepatocellular
carcinoma (Study
22)
Oh, Do-Youn Phase II study Abstract #4520
assessing Poster #128Poster Session - Gastrointestinal
tolerability, Cancer: Gastroesophageal, Pancreatic, and
efficacy and Hepatobiliary
biomarkers for
durvalumab ±
tremelimumab and
gemcitabine/cispla
tin in chemo
-naïve advanced
biliary tract
cancer
Lim, E A Phase I, open Abstract #5518
-label multi Poster #99Poster Session - Genitourinary
-center study to Cancer - Prostate, Testicular, and Penile
assess the
safety,
pharmacokinetics,
and the
preliminary
antitumor
activity of
AZD4635 both as
monotherapy and
in combination in
patients with
advanced solid
malignancies:
results from
prostate cancer
patients
DNA damage
response
Poveda, A Final overall Abstract #6002Oral Abstract Session -
survival results Gynecologic Cancer
from SOLO2: a
Phase III trial
assessing
maintenance
olaparib in
patients with
platinum
-sensitive,
relapsed ovarian
cancer and a BRCA
mutation
Cadoo, K Olaparib Abstract #6013
treatment in Poster #184Poster Discussion - Gynecologic
patients with Cancer
platinum
-sensitive
relapsed ovarian
cancer by BRCA
mutation and
homologous
recombination
deficiency
status: Phase II
LIGHT study
Lee, J Cediranib in Abstract #6056
combination with Poster #227Poster Session - Gynecologic Cancer
olaparib in
patients without
a germline
BRCA1/2 mutation
with recurrent
platinum
-resistant
ovarian cancer:
Phase IIb
CONCERTO trial
Poveda, A Olaparib Abstract #6057
maintenance Poster #228Poster Session - Gynecologic Cancer
monotherapy for
non-germline
BRCA1/2-mutated
platinum
-sensitive
relapsed ovarian
cancer patients:
Phase IIIb
OPINION interim
analysis
Liu, J A Phase III study Abstract #6003Oral Abstract Session -
comparing single Gynecologic Cancer
-agent olaparib
or the
combination of
cediranib and
olaparib to
standard platinum
-based
chemotherapy in
recurrent
platinum
-sensitive
ovarian cancer
Gelmon, K Real-world Abstract #1087Poster #172Poster Session -
clinical Breast Cancer - Metastatic
effectiveness and
safety of
olaparib
monotherapy in
HER2-negative
gBRCA-mutated
metastatic breast
cancer: Phase
IIIb LUCY interim
analysis
Tumour
drivers and
resistance
Herbst, R Osimertinib as Abstract #LBA5Plenary Session
adjuvant therapy Sunday 31 May, 1:00pm EDT
in patients with
Stage IB-IIIA
EGFRm NSCLC after
complete tumor
resection: ADAURA
Lu, S Phase II study of Abstract #9519Poster #285Poster Discussion -
savolitinib in Lung Cancer - Non-Small Cell Metastatic
patients with
pulmonary
sarcomatoid
carcinoma and
other types of
NSCLC harboring
MET exon 14
skipping
mutations
Choueiri, T SAVOIR: A Phase Abstract #5002Oral Abstract Session -
III study of Genitourinary Cancer - Kidney and Bladder
savolitinib vs.
sunitinib in
patients with MET
-driven papillary
renal cell
carcinoma
Julia, K Concurrent Abstract # 9507Oral Abstract Session - Lung
osimertinib plus Cancer- Non-Small Cell Metastatic
gefitinib for
first-line
treatment of EGFR
-mutated NSCLC
Piotrowska, ECOG-ACRIN 5162: Abstract #9513Poster #279Poster Discussion -
Z A Phase II study Lung Cancer - Non-Small Cell Metastatic
of osimertinib
160 mg in NSCLC
with EGFR exon 20
insertions
Hamilton, E A Phase I dose Abstract #1024Poster #109Poster Discussion -
escalation and Breast Cancer - Metastatic
expansion study
of the next
generation
oral SERD AZD9833
in women with ER
-positive, HER2
-negative
advanced breast
cancer (SERENA-1)
Schmid, P A Phase III trial Abstract #TPS1109Poster #194Poster Session -
of capivasertib Breast Cancer - Metastatic
and paclitaxel in
first-line
treatment of
patients with
metastatic triple
-negative breast
cancer
(CAPItello290)
Haematology
Ghia, P Acalabrutinib vs Abstract #8015Poster #348Poster Discussion -
Idelalisib plus Hematologic Malignancies - Lymphoma and
Rituximab or Chronic Lymphocytic Leukemia
Bendamustine plus
Rituximab in
Relapsed/Refractor
y Chronic
Lymphocytic
Leukemia: ASCEND
Final Results
Byrd, C Acalabrutinib in Abstract #8024Poster #357Poster Session -
Treatment-Naïve Hematologic Malignancies - Lymphoma and
Chronic Chronic Lymphocytic Leukemia
Lymphocytic
Leukemia: Mature
Results From
Phase II Study
Demonstrating
Durable
Remissions and
Long-Term
Tolerability
Furman, R Safety of Abstract #8064Poster #397Poster Session -
Acalabrutinib Hematologic Malignancies - Lymphoma and
Monotherapy in Chronic Lymphocytic Leukemia
Hematologic
Malignancies:
Pooled Analysis
From Clinical
Trials
Antibody
drug
conjugates
Smit, E Trastuzumab Abstract # 9504Oral Abstract Session - Lung
deruxtecan in Cancer- Non-Small Cell Metastatic
patients with
HER2-mutated
metastatic NSCLC:
Interim results
of DESTINY-Lung01
Shitara, K Trastuzumab Abstract #4513Poster #121Poster Session -
deruxtecan in Gastrointestinal Cancer - Gastroesophageal,
patients with Pancreatic, and Hepatobiliary
HER2-positive
advanced gastric
or
gastroesophageal
junction
adenocarcinoma: A
randomized, Phase
II, multicenter,
open-label study
(DESTINY
-Gastric01)
Siena, S A Phase II, Abstract #4000Oral Abstract Session -
multicenter, open Gastrointestinal Cancer - Colorectal and Anal
-label study of
trastuzumab
deruxtecan in
patients with
HER2-expressing
metastatic
colorectal
cancer: DESTINY
-CRC01
Modi, S Trastuzumab Abstract #1036Poster #121Poster Session -
deruxtecan for Breast Cancer- Metastatic
HER2-positive
metastatic breast
cancer: DESTINY
-Breast01
subgroup analysis
1. Beginning Friday, 29 May 2020 8:00 AM EDT oral presentations, poster discussions and poster sessions will be available on demand for 180 days including video and slide presentations and discussant commentary.
AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. With six new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to AstraZeneca's main capabilities, the Company is actively pursuing innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by the investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms - Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates - and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).